Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22520688 | 0.87 | HRH3 (0.33) | HRH3 | |
| SCHEMBL22520604 | 0.86 | HRH3 (0.36) | CYP2D6SMN1; SMN2HRH3 | |
| SCHEMBL22520629 | 0.85 | HRH3 (0.32) | HRH3 | |
| SCHEMBL24475334 | 0.84 | TSHR (0.36) | — | |
| SCHEMBL24475297 | 0.82 | HRH3 (0.30) | HRH3 | |
| SCHEMBL22520701 | 0.81 | CACNA2D1 (0.36) | CYP2D6SMN1; SMN2HRH3 | |
| SCHEMBL22520762 | 0.80 | ACHE (0.35) | CYP2D6SMN1; SMN2HRH3 | |
| SCHEMBL29317115 | 0.80 | CYP2D6 (0.33) | CYP2D6SMN1; SMN2HRH3 | |
| SCHEMBL24480557 | 0.79 | CYP1A2 (0.32) | CYP2D6 | |
| SCHEMBL20148098 | 0.79 | CYP2D6 (0.35) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | CYP2D6 304/4885SMN1; SMN2 3884/4885HRH3 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.